Pleural Diseases

July 15, 2002

Positive results were reported from a phase I/II trial of NicOx's NCX 950, an inhaled nitric oxide-donating drug for respiratory diseases. The randomized, double-blind, placebo-controlled trial was conducted in Switzerland and included 24 healthy subjects. The study was designed to compare treatment with an inhaled formulation of NCX 950 to treatment with salbutamol sulphate and placebo. Results indicated that NCX 950 was safe and well tolerated. Furthermore, data showed equipotency for NCX 950 in terms of bronchodilation and a faster onset of action compared to salbutamol.

Related Medical Areas